SLP vs. NXGN, UIS, AUR, AGYS, VRNT, IONQ, NTCT, TDCX, MDRX, and DMRC
Should you be buying Simulations Plus stock or one of its competitors? The main competitors of Simulations Plus include NextGen Healthcare (NXGN), Unisys (UIS), Aurora Innovation (AUR), Agilysys (AGYS), Verint Systems (VRNT), IonQ (IONQ), NetScout Systems (NTCT), TDCX (TDCX), Veradigm (MDRX), and Digimarc (DMRC).
NextGen Healthcare (NASDAQ:NXGN) and Simulations Plus (NASDAQ:SLP) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their media sentiment, institutional ownership, dividends, analyst recommendations, profitability, risk, valuation, community ranking and earnings.
In the previous week, Simulations Plus had 4 more articles in the media than NextGen Healthcare. MarketBeat recorded 6 mentions for Simulations Plus and 2 mentions for NextGen Healthcare. NextGen Healthcare's average media sentiment score of 0.74 beat Simulations Plus' score of 0.52 indicating that Simulations Plus is being referred to more favorably in the news media.
Simulations Plus received 129 more outperform votes than NextGen Healthcare when rated by MarketBeat users. Likewise, 62.82% of users gave Simulations Plus an outperform vote while only 50.71% of users gave NextGen Healthcare an outperform vote.
Simulations Plus has lower revenue, but higher earnings than NextGen Healthcare. NextGen Healthcare is trading at a lower price-to-earnings ratio than Simulations Plus, indicating that it is currently the more affordable of the two stocks.
Simulations Plus has a net margin of 16.22% compared to Simulations Plus' net margin of -0.89%. Simulations Plus' return on equity of 11.37% beat NextGen Healthcare's return on equity.
NextGen Healthcare has a beta of 0.77, suggesting that its stock price is 23% less volatile than the S&P 500. Comparatively, Simulations Plus has a beta of 0.68, suggesting that its stock price is 32% less volatile than the S&P 500.
76.7% of NextGen Healthcare shares are held by institutional investors. Comparatively, 78.1% of Simulations Plus shares are held by institutional investors. 4.6% of NextGen Healthcare shares are held by company insiders. Comparatively, 20.9% of Simulations Plus shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
NextGen Healthcare currently has a consensus price target of $22.98, suggesting a potential downside of 4.01%. Simulations Plus has a consensus price target of $51.00, suggesting a potential upside of 2.51%. Given NextGen Healthcare's stronger consensus rating and higher probable upside, analysts plainly believe Simulations Plus is more favorable than NextGen Healthcare.
Summary
Simulations Plus beats NextGen Healthcare on 15 of the 18 factors compared between the two stocks.
Get Simulations Plus News Delivered to You Automatically
Sign up to receive the latest news and ratings for SLP and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding SLP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Simulations Plus Competitors List
Related Companies and Tools
